Abstract
AbstractHormone-related cancers, specifically breast, endometrium, ovary, and prostate, show a distinctive mechanism of carcinogenesis. The occurrence of cancer depends upon the endogenous and exogenous hormones-driven cell proliferation that also leads to genetic modification. Management of hormonal cancer includes the implementation of newer strategies for early detection and prevention of hormonal cancer metastasis. Owing to the limitation of the traditional drug delivery system, advanced targeting drug delivery systems is employed in the management of hormonal cancer. Nanotechnology-based drug delivery systems like lipid-based carrier systems (solid lipid nanoparticles), liposomes, polymeric nanoparticles, inorganic nanoparticles, caron nanotubes, and other carrier systems are routinely employed. Besides, peptide and nucleic acid-based (DNA and siRNA) technology is recently used to target the desired receptors which are over-expressed over tumour mass.KeywordsHormonal cancerNanotechnologyNanocarriersReceptorHormone
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
